NIKKEI 225
27,416.73 -16.67 (-0.06%) HANG SENG
22,067.20 -2.53 (-0.01%) CRUDE OIL
77.91 +0.01 (+0.01%) GOLD FUTURES
1,940.10 +0.90 (+0.05%) DOW
33,717.09 -260.99 (-0.77%) BTC-GBP
18,510.60 -680.18 (-3.54%)
NVO Mar 2023 70.000 put
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 70.00 |
| Expiry date | 2023-03-17 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
- Reuters
Drugmakers prevail in dispute over U.S. discount drug program
(Reuters) -Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday. The ruling from a three-judge panel of the 3rd U.S. Circuit Court of Appeals based in Philadelphia is a victory for Sanofi SA, Novo Nordisk AS and AstraZeneca PLc. The companies had sued the U.S. Department of Health and Human Services (HHS) after it ordered them to stop restricting sales of discounted drugs to so-called contract pharmacies.
- Zacks
Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod
The FDA approves Eli Lilly's Jaypirca (pirtobrutinib) under an accelerated approval pathway as a treatment for mantle cell lymphoma (MCL).
- Zacks
Merck (MRK) to Report Q4 Earnings: What's in the Cards?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda when the company reports Q4 earnings.
